Human Pluripotent Stem Cells: Progress to Therapy
08 April 2013 - 10 April 2013
This meeting will focus on the potential for using human embryonic and induced pluripotent stem cells in regenerative medicine, and will also explore the ways in which developmental biology has informed how stem cells might be manipulated.
The past 15 years have seen a rapid growth in interest in human pluripotent stem cells, first embryonic stem cells and, more recently, induced pluripotent stem cells, not only for regenerative medicine but also for toxicology, disease modelling and drug discovery. Development of these applications depends on our fundamental understanding of how such cells make fate decisions between self-renewal on the one hand, and differentiation into distinct lineages on the other.
Considerable progress has already been made and, today, applications in all of these areas are now on the horizon, and some clinical trials for regenerative medicine have begun. However, much still remains to be done, and our knowledge of the mechanisms that guide development of the embryo is central to understanding how to manipulate pluripotent stem cells.
In this meeting we will bring together key researchers from India and the UK to discuss the progress in developing applications for pluripotent human stem cells and to address how developmental biology is contributing to that progress.
The Octagon Centre, Western Bank, Sheffield, S10 2TN
http://onlineshop.shef.ac.uk/browse/extra_info.asp?compid=1&modid=2&prodid=140&deptid=6&searchresults=1
ADME & Predictive Toxicology
11 April 2013 - 12 April 2013
The 2013 ADME & Predictive Toxicology Congress will report on the vital role ADME and Predictive Toxicology play in aiding successful drug candidate identification and design. Ensuring drugs make it to the market quicker with higher hit rates and earlier indications of human toxicity issues, is of the utmost importance and will be discussed at length here.
Our array of keynote speakers will give presentations on all areas of ADME/Tox backed up by a panel of experts speaking on highly relevant and “hot” topics: Pharmacogenomics and Drug Safety, Genotoxicity and Toxicokinetic Modeling, ADME Optimisation for Drug Design/Discovery, ADME and Metabolomics, New Therapeutic Targets in Drug Design/Discovery and Regulatory Issues in ADME.
Barcelona, Spain
http://www.chemistry-conferences.com/2013/04/11%20-%2012%20ADME%20and%20Predictive%20Toxicology%20(Barcelona%20-%20ES).htm
Proteinase 2013 – 8th RSC-SCI Symposium on Proteinase Inhibitor Design
15 April 2013 - 16 April 2013
This symposium will cover progress in the design and synthesis of protease inhibitors for a diverse range of disease indications, while also covering a range of novel drug discovery activities: from 'Molecules to Medicines’.
Novartis, Basel, Switzerland
http://www.rsc.org/ConferencesAndEvents/conference/alldetails.cfm?evid=112031
Proteinase 2013 – 8th RSC-SCI Symposium on Proteinase Inhibitor Design
15 April 2013 - 16 April 2013
This symposium will cover progress in the design and synthesis of protease inhibitors for a diverse range of disease indications, while also covering a range of novel drug discovery activities: from 'Molecules to Medicines’.
Novartis, Basel, Switzerland
http://www.rsc.org/ConferencesAndEvents/conference/alldetails.cfm?evid=112031
9th Annual PEGS
29 April 2013 - 03 May 2013
Year after year, PEGS challenges attendees to
evolve their thinking around the generation,
characterization, and clinical application of
proteins. Join over 1,200 of your colleagues
this April in Boston to make your mark on the
rapidly changing landscape of protein and
antibody engineering.
Seaport World Trade Center, Boston, MA, USA
http://www.pegsummit.com/PEGS_Content.aspx?id=120724&libID=120672
3rd Diabetes Summit
29 April 2013 - 30 April 2013
This event is the only diabetes conference that provides delegates the opportunity to facilitate discussions and collaborations among affiliations (industry, academia, government) that can lead to the advancement of therapeutics and development of drugs/treatments for diabetes, and hopefully one day a cure. In addition the conference will provide updated educational research on various novel targets, therapeutics, developments, and technologies; regulatory guidance; case studies on successful and/or unsuccessful clinical trials; and other relevant insights that can help delegates advance their own research and therapeutics.
Hyatt Regency, Boston, MA, USA
http://www.gtcbio.com/component/conference/?file=home&cn=Diabetes+Summit+2013&cid=115
10th Stem Cell Summit
29 April 2013 - 30 April 2013
Recent developments in pre-clinical and clinical trials of stem cell therapy, regenerative medicine and tissue engineering, cancer stem cells, stem cell reprogramming, and regulatory policies regarding stem cell research will be addressed. In addition, focuses on the business opportunities, challenges and potential strategies for overcoming these challenges will be addressed. What categories of companies are currently commercially viable? How are they being funded? What kind of strategic relationships are available within the industry?
Hyatt Regency, Boston, MA, USA
http://www.gtcbio.com/index.php?option=com_conference&file=home&cn=Stem%20Cell%20Summit%202013&cid=22
BioScotland 2013
30 April 2013
BioScotland 2013 is being organised by The Allancia Group in conjunction with the University of Strathclyde, as part of the University of Strathclyde’s ‘Engage with Strathclyde’ week of events
The event will seek to provide a platform for delegates to meet like minded people and discuss ideas and exchanges possible solutions while building strong collaborations and business connections for the future.
The Barony Hall, The University of Strathclyde, Glasgow, Scotland
http://www.bioscotland.co.uk/